Related Experiment Video

Updated: Sep 22, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis

Dong Liang1, Chuanjie Tian2, Xiaowen Zhang3

  • 1Department of Urology Surgery, Binhai County Hospital of TCM, Yancheng, Jiangsu 224500, P.R. China.

Molecular Medicine Reports
|May 26, 2022
PubMed

Insights

Long non-coding RNA MNX1 Antisense RNA 1 (MNX1-AS1) promotes prostate cancer by regulating the miR-2113/MDM2 axis. Silencing MNX1-AS1 inhibits tumor growth, migration, and invasion, offering a potential therapeutic target for prostate cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in human cancers.
  • The specific function and mechanism of lncRNA MNX1 Antisense RNA 1 (MNX1-AS1) in prostate cancer remain largely unexplored.

Purpose of the Study:

  • To investigate the role of MNX1-AS1 in prostate cancer development and progression.
  • To elucidate the underlying molecular mechanism involving microRNA-2113 (miR-2113) and murine double min 2 (MDM2).

Main Methods:

  • Quantitative PCR and Western blotting were used to assess MNX1-AS1, miR-2113, and MDM2 expression in prostate cancer tissues and cell lines.
  • In vitro cell assays (proliferation, migration, invasion) and in vivo tumor formation experiments were conducted.
  • Dual luciferase reporter assays confirmed interactions between MNX1-AS1, miR-2113, and MDM2.

Main Results:

  • MNX1-AS1 expression was significantly upregulated in prostate cancer tissues and cells.
  • Knockdown of MNX1-AS1 inhibited cell viability, migration, invasion, and tumor growth.
  • MNX1-AS1 was found to target miR-2113, which in turn targets MDM2, indicating an MNX1-AS1/miR-2113/MDM2 regulatory axis.

Conclusions:

  • MNX1-AS1 promotes prostate cancer progression by modulating the miR-2113/MDM2 pathway.
  • Targeting MNX1-AS1 presents a potential therapeutic strategy for prostate cancer treatment.
Keywords:
lncRNA MNX1 antisense RNA 1microRNA 2113murine double min‑2prostate cancer

More Related Videos

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K
CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis10:40

CRISPR Gene Editing Tool for MicroRNA Cluster Network Analysis

Published on: April 25, 2022

2.5K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.4K
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
9.0K